Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXFP1 | Q9HBX9 | 4/20 | 0.48 |
| ▸ | IDO1 | P14902 | 2/20 | 0.48 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.47 |
| ▸ | HTR3B | O95264 | 1/20 | 0.47 |
| ▸ | HTR3A | P46098 | 1/20 | 0.47 |
| ▸ | HTR3D | Q70Z44 | 1/20 | 0.47 |
| ▸ | HTR3C | Q8WXA8 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | RORB | Q92753 | 4/20 | 0.44 |
| ▸ | RORC | P51449 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | CRHR1 | P34998 | 1/20 | 0.43 |
| ▸ | NOS3 | P29474 | 2/20 | 0.42 |
| ▸ | NOS1 | P29475 | 2/20 | 0.42 |
| ▸ | NOS2 | P35228 | 2/20 | 0.42 |
| ▸ | ESR1 | P03372 | 1/20 | 0.42 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12289344 | 1.00 | RXFP1 (0.48) | RXFP1IDO1HTR3EHTR3BHTR3A | |
| SCHEMBL2419984 | 1.00 | RXFP1 (0.48) | RXFP1IDO1HTR3EHTR3BHTR3A | |
| SCHEMBL1696031 | 0.75 | RXFP1 (0.63) | RXFP1MAPTLMNAGAAKDM4E | |
| SCHEMBL1696028 | 0.75 | RXFP1 (0.63) | RXFP1MAPTLMNAGAAKDM4E | |
| SCHEMBL29579640 | 0.72 | IDO1 (0.58) | IDO1HTR3EHTR3BHTR3AHTR3D | |
| SCHEMBL4436230 | 0.70 | CTSD (0.47) | RXFP1MAPTTSHRGAAALDH1A1 | |
| SCHEMBL11504586 | 0.69 | RORB (0.60) | RXFP1MAPTLMNATSHRRORB | |
| SCHEMBL5491795 | 0.69 | RXFP1 (0.88) | RXFP1MAPT | |
| SCHEMBL29870252 | 0.69 | HTR3E (0.64) | IDO1HTR3EHTR3BHTR3AHTR3D | |
| SCHEMBL4928790 | 0.68 | IDO1 (0.55) | RXFP1IDO1HTR3EHTR3BHTR3A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110237679-A1 | NOVEL ANTIVIRAL COMPOUNDS, COMPOSITIONS, AND METHODS OF USE | CYTOKINE PHARMASCIENCES, INC. (US) | 2011-09-29 | — | — | US | disclosed |
| WO-2010077734-A2 | NOVEL ANTIVIRAL COMPOUNDS, COMPOSITIONS, AND METHODS OF USE | CYTOKINE PHARMASCIENCES, INC. (US) | 2010-07-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110237679-A1 | NOVEL ANTIVIRAL COMPOUNDS, COMPOSITIONS, AND METHODS OF USE | SARS1, EIF2AK2, MAVS | RXFP1 4844/4885IDO1 644/4885HTR3E 2782/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.